131 related articles for article (PubMed ID: 26906105)
21. Value of immunohistochemical expression of podocalyxin in active lupus nephritis.
Behairy MA; Shakweer MM; El Said TW; ElGharbawy NH
Nefrologia (Engl Ed); 2018; 38(1):64-72. PubMed ID: 28757276
[TBL] [Abstract][Full Text] [Related]
22. Monocyte chemoattractant protein-1 is excreted in excessive amounts in the urine of patients with lupus nephritis.
Noris M; Bernasconi S; Casiraghi F; Sozzani S; Gotti E; Remuzzi G; Mantovani A
Lab Invest; 1995 Dec; 73(6):804-9. PubMed ID: 8558841
[TBL] [Abstract][Full Text] [Related]
23. Urinary monocyte chemoattractant protein 1 and alpha 1 acid glycoprotein as biomarkers of renal disease activity in juvenile-onset systemic lupus erythematosus.
Watson L; Midgley A; Pilkington C; Tullus K; Marks S; Holt R; Jones C; Beresford M
Lupus; 2012 Apr; 21(5):496-501. PubMed ID: 22147846
[TBL] [Abstract][Full Text] [Related]
24. The use of the British Isles Lupus Assessment Group (BILAG) index as a valid tool in assessing disease activity in childhood-onset systemic lupus erythematosus.
Marks SD; Pilkington C; Woo P; Dillon MJ
Rheumatology (Oxford); 2004 Sep; 43(9):1186-9. PubMed ID: 15226518
[TBL] [Abstract][Full Text] [Related]
25. Urinary podocyte loss is a more specific marker of ongoing glomerular damage than proteinuria.
Yu D; Petermann A; Kunter U; Rong S; Shankland SJ; Floege J
J Am Soc Nephrol; 2005 Jun; 16(6):1733-41. PubMed ID: 15829708
[TBL] [Abstract][Full Text] [Related]
26. Urinary TWEAK and the activity of lupus nephritis.
Schwartz N; Su L; Burkly LC; Mackay M; Aranow C; Kollaros M; Michaelson JS; Rovin B; Putterman C
J Autoimmun; 2006 Dec; 27(4):242-50. PubMed ID: 17257812
[TBL] [Abstract][Full Text] [Related]
27. [Feasibility of SLEDAI-2000 and BILAG-2004 scoring systems for assessing renal disease activity in children with lupus nephritis].
Zhou JQ; Jiang H
Zhongguo Dang Dai Er Ke Za Zhi; 2012 Oct; 14(10):775-9. PubMed ID: 23092572
[TBL] [Abstract][Full Text] [Related]
28. Frequency of class III and IV nephritis in systemic lupus erythematosus without clinical renal involvement: an analysis of predictive measures.
Wakasugi D; Gono T; Kawaguchi Y; Hara M; Koseki Y; Katsumata Y; Hanaoka M; Yamanaka H
J Rheumatol; 2012 Jan; 39(1):79-85. PubMed ID: 22089455
[TBL] [Abstract][Full Text] [Related]
29. Urinary neutrophil gelatinase-associated lipocalin as a biomarker of nephritis in childhood-onset systemic lupus erythematosus.
Brunner HI; Mueller M; Rutherford C; Passo MH; Witte D; Grom A; Mishra J; Devarajan P
Arthritis Rheum; 2006 Aug; 54(8):2577-84. PubMed ID: 16868980
[TBL] [Abstract][Full Text] [Related]
30. Urinary protein/creatinine ratio versus 24-hour proteinuria in the evaluation of lupus nephritis.
Solorzano GT; Silva MV; Moreira SR; Nishida SK; Kirsztajn GM
J Bras Nefrol; 2012 Mar; 34(1):64-7. PubMed ID: 22441184
[TBL] [Abstract][Full Text] [Related]
31. Estimation of monocyte-chemoattractantprotein-1 (Mcp-1) level in patients with lupus nephritis.
Alzawawy A; Zohary M; Ablordiny M; Eldalie M
Int J Rheum Dis; 2009 Dec; 12(4):311-8. PubMed ID: 20374368
[TBL] [Abstract][Full Text] [Related]
32. Anti-C1q antibodies in nephritis: correlation between titres and renal disease activity and positive predictive value in systemic lupus erythematosus.
Marto N; Bertolaccini ML; Calabuig E; Hughes GR; Khamashta MA
Ann Rheum Dis; 2005 Mar; 64(3):444-8. PubMed ID: 15286009
[TBL] [Abstract][Full Text] [Related]
33. Growing international evidence for urinary biomarker panels identifying lupus nephritis in children - verification within the South African Paediatric Lupus Cohort.
Smith EMD; Lewandowski LB; Jorgensen AL; Phuti A; Nourse P; Scott C; Beresford MW
Lupus; 2018 Dec; 27(14):2190-2199. PubMed ID: 30348048
[TBL] [Abstract][Full Text] [Related]
34. Urinary osteoprotegerin: a potential biomarker of lupus nephritis disease activity.
Gupta R; Aggarwal A; Sinha S; Rajasekhar L; Yadav A; Gaur P; Misra R; Negi VS
Lupus; 2016 Oct; 25(11):1230-6. PubMed ID: 26936893
[TBL] [Abstract][Full Text] [Related]
35. Elevated serum levels of syndecan-1 are associated with renal involvement in patients with systemic lupus erythematosus.
Kim KJ; Kim JY; Baek IW; Kim WU; Cho CS
J Rheumatol; 2015 Feb; 42(2):202-9. PubMed ID: 25512478
[TBL] [Abstract][Full Text] [Related]
36. Antinucleosome antibodies as a potential biomarker for the evaluation of renal pathological activity in patients with proliferative lupus nephritis.
Hung WT; Chen YM; Lan JL; Chen HH; Chen YH; Chen DY; Hsieh CW; Wen MC
Lupus; 2011 Nov; 20(13):1404-10. PubMed ID: 21946514
[TBL] [Abstract][Full Text] [Related]
37. Urinary podocyte excretion and proteinuria in patients treated with antivascular endothelial growth factor therapy for solid tumor malignancies.
Hayman SR; Calle JC; Jatoi A; Craici IM; Wagner SJ; Weaver AL; Greene EL; Grande JP; Garovic VD
Oncology; 2014; 86(5-6):271-8. PubMed ID: 24902997
[TBL] [Abstract][Full Text] [Related]
38. Urinary CXCL10: a marker of nephritis in lupus patients.
Marie MA; Abu Khalil RE; Habib HM
Reumatismo; 2014 Mar; 65(6):292-7. PubMed ID: 24705033
[TBL] [Abstract][Full Text] [Related]
39. Comparative value of urinalysis, urine cytology and urine sIL2R in the assessment of renal disease in patients with systemic lupus erythematosus (SLE).
Roberti I; Dikman S; Spiera H; Reisman L; Eichenfield AH; Lieberman KV
Clin Nephrol; 1996 Sep; 46(3):176-82. PubMed ID: 8879852
[TBL] [Abstract][Full Text] [Related]
40. Urine osteoprotegerin and monocyte chemoattractant protein-1 in lupus nephritis.
Kiani AN; Johnson K; Chen C; Diehl E; Hu H; Vasudevan G; Singh S; Magder LS; Knechtle SJ; Petri M
J Rheumatol; 2009 Oct; 36(10):2224-30. PubMed ID: 19648301
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
